precisionmedicineonline6d
BMS's Opdivo-Yervoy Combo Approved in Europe for First-Line Treatment of Certain Colorectal Cancers
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
precisionmedicineonline6d
European Commission Approves AstraZeneca's Tagrisso in Unresectable EGFR-Mutated NSCLC
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
precisionmedicineonline6d
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
precisionmedicineonline8d
Inceptor Bio Licenses Solid Tumor CAR T-Cell Therapy to Grit Bio in China
The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.
precisionmedicineonline9d
Institute for Follicular Lymphoma Innovation Invests $11M in PeproMene Bio's CAR T-Cell Therapy
R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.
precisionmedicineonline9d
HHS Releases List of Medicare Part B Drugs Subject to Rebate Program
The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.